Cancer drug delivery最新文献_第5页

Growth of carcinoma of the esophagus and gastroesophageal junction in a human tumor cloning assay. 人肿瘤克隆实验中食管癌和胃食管交界处癌的生长。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.273

G J Harris, J N Turner, D D Von Hoff

{"title":"Growth of carcinoma of the esophagus and gastroesophageal junction in a human tumor cloning assay.","authors":"G J Harris, J N Turner, D D Von Hoff","doi":"10.1089/cdd.1986.3.273","DOIUrl":"https://doi.org/10.1089/cdd.1986.3.273","url":null,"abstract":"We have received and attempted to culture 23 specimens from 23 patients with squamous cell carcinoma of the esophagus and 15 specimens from 11 patients with adenocarcinoma of the gastroesophageal junction (GEJ). Evaluable growth, defined as greater than or equal to 20 tumor colonies per control plate, was achieved in 35% of the esophageal specimens and in 40% of the GEJ specimens. The specimens with evaluable growth yielded 20 evaluable drug tests for the esophageal group and 42 evaluable drug tests for the GEJ group. A positive response to the chemotherapeutic agent, defined as less than or equal to 50% survival in the drug treated plates relative to the control plates, was seen in 1 (5%) of the evaluable esophageal specimens and in 20 (47%) of the evaluable GEJ specimens. The only agent active in the esophageal group was cis-platinum (1 of 5 tests). Standard active agents in the GEJ group included: 5-fluorouracil (1 of 1 test), vinblastine (4 of 8 tests), vincristine (1 of 1 test), and VP-16 (1 of 1 test). Active investigational agents included: methylglyoxalbisguanylhydrazone (MGBG) (1 of 1 test), auranofin (3 of 3 tests), vinzolidine (4 of 6 tests), carbetimer (2 of 2 tests), and ametantrone (3 of 3 tests). The cloning results are consistent with the clinical observation that carcinoma of the esophagus and GEJ respond differently to chemotherapy.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"3 4","pages":"273-8"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1986.3.273","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14690357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Totally implantable catheters for cancer chemotherapy: French experience on 325 cases. 全植入式导尿管用于癌症化疗:法国325例的经验。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.131

G Champault

引用次数: 13

Cis platine (CDDP) in continuous intravenous ambulatory infusion: a new method of administration. 顺铂(CDDP)在连续静脉动态输注中的应用:一种新的给药方法。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.183

M Benahmed, J Renaux, M Spielman, J Rouesse

引用次数: 6

The influence of route of administration on the hepatic uptake of methotrexate. 给药途径对甲氨蝶呤肝吸收的影响。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.239

F M Balis, R F Murphy, C M Lester, D G Poplack

引用次数: 2

The influence of monoclonal antibody dose on tumor uptake of radiolabeled antibody. 单克隆抗体剂量对肿瘤放射性标记抗体摄取的影响。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.243

R L Wahl, M Liebert, B S Wilson

引用次数: 23

Comparison of mitoxantrone and ametantrone in human acute myelocytic leukemia cells in culture and in bone marrow granulocyte-macrophage progenitor cells. 米托蒽醌和阿美醌在人急性髓细胞白血病培养细胞和骨髓粒细胞-巨噬细胞祖细胞中的作用比较。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.93

G Fountzilas, T Ohnuma, K Rammos, B Mindich, J F Holland

引用次数: 8

Low dose ara-C administered by continuous subcutaneous infusion: a pharmacologic evaluation. 持续皮下输注低剂量ara-C:药理学评价。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.211

D R Spriggs, J E Sokal, J Griffin, D W Kufe

引用次数: 4

Controlled studies of a new microprocessor-based portable infusion pump. 一种新型微处理器便携式输液泵的对照研究。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.139

R T Dorr, S E Salmon, M E Marsh, A Robertone

{"title":"Controlled studies of a new microprocessor-based portable infusion pump.","authors":"R T Dorr, S E Salmon, M E Marsh, A Robertone","doi":"10.1089/cdd.1986.3.139","DOIUrl":"https://doi.org/10.1089/cdd.1986.3.139","url":null,"abstract":"A new microprocessor-controlled portable infusion pump, the Pancretec Provider IV 2000 TM was tested in vitro and in vivo in cancer patients. The Provider is a rotary peristaltic, battery-powered pump capable of flow rates of 0.2 to 83 ml/hour with delivery volumes up to 1999 ml. Two programming modes are available: intermittent infusion and continuous infusion. Bench tests showed the flow rate accuracy to be within 96% of the desired rate. Flow rate precision was similarly excellent at +/- 2%. Clinical studies were performed in 14 ambulatory patients receiving continuous infusion antineoplastic or analgesic drugs over 5-60 days as outpatients. The majority of infusions delivered fluoropyrimidines via indwelling central venous access ports. Two of the patients received long term (60 days) continuous infusion of analgesics for pain control. Flow rate accuracy with the pumps was within +/- 5% in 90% of the 27 infusion courses (244 patient-days of continuous infusion therapy). A significant therapy deviation (interruption 10% of the desired course) occurred in three instances. One related to a procedural error (incomplete cartridge insertion into the pump), two were caused by fluid leakage which interrupted pump function. Defect alarms (both visual and audible) operated in both instances. A KVO flow rate of 0.1 ml/hr was also found to be adequate to maintain catheter patency in peripheral veins over a 24-hour period in two normal volunteers. We conclude that the Provider pump is an accurate, reliable and state of the art infusion system with wide clinical applicability.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"3 2","pages":"139-46"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1986.3.139","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14827810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Phase II trial of intracarotid BCNU and cisplatin in primary malignant brain tumors. 颈动脉内BCNU联合顺铂治疗原发性恶性脑肿瘤的II期临床试验。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.147

L G Feun, Y Y Lee, W K Yung, C Charnsangavej, N Savaraj, R A Tang, S Wallace

{"title":"Phase II trial of intracarotid BCNU and cisplatin in primary malignant brain tumors.","authors":"L G Feun, Y Y Lee, W K Yung, C Charnsangavej, N Savaraj, R A Tang, S Wallace","doi":"10.1089/cdd.1986.3.147","DOIUrl":"https://doi.org/10.1089/cdd.1986.3.147","url":null,"abstract":"Intracarotid BCNU (100 mg/m2) and cisplatin (60 mg/m2) were administered to 36 patients with malignant brain tumors recurrent or progressive after cranial irradiation. Courses of therapy were repeated at 4-6 week intervals. Of 23 evaluable patients with recurrent glioma, 9 (39%) had tumor regression by CT scan and 3 had stable disease. The median time to tumor progression for responding patients was 37 weeks. For all patients with primary tumors it was 14 weeks. Six of 9 patients with no prior chemotherapy had a response and 1 had stable disease. Of 14 patients who had received prior chemotherapy, 3 had a response and 2 had stable disease. Survival ranged from 9 weeks to 95+ weeks (median 34 weeks) from start of therapy. Six of 23 patients with primary tumors are alive 1 year or more following therapy. Four of 11 patients with brain metastases had a response and 2 had stable disease. Major neurologic toxicity of intracarotid BCNU and cisplatin appeared cumulative and consisted of reversible hemiparesis in 3% of 118 courses, TIA in 1%, expressive aphasia in 9%, lethargy in 3%, seizures in 12%, and reversible confusion in 1%. Retinal toxicity consisted of mild blurring of vision in 4 patients and ipsilateral blindness in 5 patients. Three of 22 patients who had received supraophthalmic infusion later developed evidence of leukoencephalopathy. Intracarotid BCNU and cisplatin appears to have modest increase in activity over intracarotid cisplatin alone (Cancer 54:794, 1984), however, neurologic and retinal toxicity may also be increased.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"3 2","pages":"147-56"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1986.3.147","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14828447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

Effect of chemical deglycosylation on the in vivo fate of ricin A-chain. 化学去糖基化对蓖麻毒素a链体内命运的影响。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.189

D C Blakey, P E Thorpe

引用次数: 47